Developer docs
API playgroundTry for free, no card

Search company profiles

Sanofi Egypt

Full company profile

uuid003pzg9

Namestring
Sanofi Egypt
Legal namestring
Sanofi S.A.
Company typeenum
Public
Founded yearint
1973
Descriptiontext

Sanofi Egypt is the Cairo-based Egyptian subsidiary of Sanofi S.A., the Paris-headquartered multinational pharmaceutical group publicly listed on Euronext Paris (ticker SAN) with ADRs on NASDAQ. Sanofi Egypt operates within Sanofi's global pharmaceutical manufacturing and commercialization network, distributing innovative medicines across multiple therapy areas — respiratory diseases, diabetes, vaccines, dermatology, cardiovascular, oncology, multiple sclerosis, rheumatology, rare diseases (Gaucher, Pompe), transplant medicine, eosinophilic esophagitis, and thyroid disorders — to Egyptian healthcare providers including hospitals, pharmacies, and patients. The subsidiary is staffed by 10,000+ employees at the global parent level with a local managing director (Adrien Delamare-Deboutteville), and participates actively in regulatory dialogue with Egypt's Drug Authority (EDA) on market access and drug system strengthening.

The company monetizes through pharmaceutical product sales distributed via established healthcare supply chains in Egypt. Pricing models are not publicly disclosed. Distribution reaches Egyptian prescribers and dispensers through standard pharma channels, with parallel support from global Sanofi digital platforms including mein.sanofi.de (patient and healthcare professional portal), the Sanofi Product Database, Medical Information services, and the parent group's Health x Tomorrow digitalization initiative. The Egypt subsidiary is governed by EDA regulatory frameworks and benefits from Sanofi's flexible, internationally-aligned regulatory engagement strategy affirmed in a 2025-11-18 meeting with EDA Chairman Dr. Ali El-Ghamrawy.

Sanofi Egypt sits within a global parent (Sanofi S.A.) that generated approximately €50.3 billion in total FY2023 revenue, with R&D infrastructure spanning biologics, technology platforms, and clinical studies. Sub-brands including Sandoz (generics) and Genzyme (rare disease biotechnology) are part of the parent's portfolio and inform the therapeutic range potentially accessible to the Egyptian market. The Egypt entity itself does not have disclosed standalone revenue, headcount, or Egypt-specific R&D investments in the available data, positioning it as a commercial/regulatory operating subsidiary rather than a standalone R&D hub.

Short descriptiontext

Sanofi Egypt is the Cairo-based Egyptian subsidiary of Paris-headquartered pharmaceutical group Sanofi S.A., distributing innovative medicines across multiple therapy areas to Egyptian hospitals, pharmacies, and patients, and engaging with Egypt's Drug Authority on regulatory and investment matters.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
10,001+
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, innovative medicines, vaccines production, biopharmaceutical research, therapy area treatments
Industry2 codes
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAF
Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceuticals
Social media profiles3 records
Cost components5 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Sandoz
Description

Generic pharmaceuticals division of Sanofi

sanofi.de
+1 more record
Core offering1 text field

Sanofi Egypt is a pharmaceutical manufacturing subsidiary that develops, manufactures, and distributes innovative medicines across multiple therapy areas including respiratory diseases, diabetes, vaccines, dermatology, cardiovascular diseases, oncology, multiple sclerosis, rheumatology, rare diseases, transplant medicine, eosinophilic esophagitis, and thyroid disorders. The company supports its pharmaceutical portfolio with digital health portals and medical information services for patients and healthcare professionals, and engages with Egypt's Drug Authority to accelerate availability of innovative medicines in the Egyptian market.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sanofi is a research-based biopharma company offering a broad portfolio of innovative therapies across multiple therapy areas including respiratory diseases (asthma, nasal polyps), diabetes, vaccines, dermatology (atopic dermatitis), cardiovascular diseases (cholesterol management), oncology, multiple sclerosis, rheumatology, rare diseases (Gaucher, Pompe), transplant medicine, eosinophilic esophagitis, and thyroid disorders. The company provides patient and healthcare professional-facing digital portals (mein.sanofi.de, product database, medical information services) alongside its therapeutic products. The product portfolio spans both pharmaceutical medications and digital health solutions under the Health x Tomorrow digitalization initiative. Research and development capabilities include biologics and technology platforms supporting drug discovery and manufacturing.

Product and service12 records
1Respiratory Disease Treatments (Atemwegserkrankungen)
CategoryTherapy Area - Respiratory
Description

Treatment solutions for respiratory conditions including asthma and nasal polyps, offered as part of Sanofi's pharmaceutical portfolio in Egypt.

2Diabetes Treatments
CategoryTherapy Area - Diabetes
Description

Diabetes treatment and management pharmaceutical solutions for patients in Egypt.

3Vaccines (Impfstoffe)
CategoryTherapy Area - Vaccines
Description

Vaccine products and immunization solutions distributed through the Egyptian healthcare supply chain.

4Dermatology Treatments (Hauterkrankungen)
CategoryTherapy Area - Dermatology
Description

Dermatological pharmaceutical treatments including atopic dermatitis.

5Cardiovascular Disease Treatments (Herz-Kreislauf-Erkrankungen)
CategoryTherapy Area - Cardiovascular
Description

Cardiovascular disease pharmaceutical treatments including cholesterol management.

6Oncology Treatments (Krebserkrankungen)
CategoryTherapy Area - Oncology
Description

Oncology pharmaceutical treatment solutions for cancer patients.

7Multiple Sclerosis Treatments (Multiple Sklerose)
CategoryTherapy Area - Neurology
Description

Neurological disorder pharmaceutical treatments for multiple sclerosis patients.

8Rheumatology Treatments (Rheumatologie)
CategoryTherapy Area - Rheumatology
Description

Rheumatological disease pharmaceutical treatments.

9Rare Disease Treatments (Seltene Erkrankungen)
CategoryTherapy Area - Rare Diseases
Description

Orphan disease pharmaceutical treatments including Gaucher disease and Pompe disease.

10Transplant Medicine Treatments (Transplantationsmedizin)
CategoryTherapy Area - Transplant
Description

Pharmaceutical treatments for transplant rejection prevention.

11Eosinophilic Esophagitis Treatments (Eosinophile Ösophagitis)
CategoryTherapy Area - Gastroenterology
Description

Specialized pharmaceutical treatment for eosinophilic esophagitis.

12Thyroid Disease Treatments (Schilddrüsenerkrankungen)
CategoryTherapy Area - Endocrinology
Description

Thyroid disorder pharmaceutical treatments including thyroid cancer.

Partnership5 partners
1Egypt's Drug Authority (EDA)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-18
Description

EDA Chairman Dr. Ali El-Ghamrawy met with Sanofi representatives to discuss mechanisms for strengthening Egypt's drug system and supporting investment. The authority affirmed commitment to flexible regulatory policies aligned with international practices to ensure accelerated availability of innovative medicines and market competitiveness. Sanofi expressed appreciation for EDA's participatory approach, stating cooperation opens prospects for further investment and treatment access in Egypt.

dailynewsegypt.com
Strategic tierMinorTypeOthers
Description

Pharmaceutical company participating alongside Sanofi in discussions with Egypt's Drug Authority regarding market stability and investment opportunities.

Strategic tierMinorTypeOthers
Description

Pharmaceutical company participating alongside Sanofi in discussions with Egypt's Drug Authority regarding market stability and investment opportunities.

Strategic tierMinorTypeOthers
Description

Pharmaceutical company participating alongside Sanofi in discussions with Egypt's Drug Authority regarding market stability and investment opportunities.

Strategic tierMinorTypeOthers
Description

Pharmaceutical company participating alongside Sanofi in discussions with Egypt's Drug Authority regarding market stability and investment opportunities.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global multinational pharmaceutical company with a presence in Egypt across oncology, cardiovascular, respiratory, and rare disease therapy areas. Co-participant with Sanofi in EDA regulatory dialogue in 2025, confirming direct market overlap and comparable business model.

TypeBroad incumbent
Description

Diversified healthcare conglomerate with pharmaceutical operations across immunology, oncology, and neuroscience, with established Egypt presence. Broader portfolio beyond pharma but directly comparable pharmaceutical subsidiary operations.

TypeRegional player
Description

Leading Egyptian pharmaceutical manufacturer with strong local market presence across branded generics and innovative medicines. Direct competitor to multinational subsidiaries like Sanofi Egypt in the domestic Egyptian pharmaceutical market.

4Abbott
TypeBroad incumbent
Description

Diversified healthcare company with pharmaceutical, diagnostics, nutritionals, and medical devices divisions, with established Egypt presence. Comparable multinational subsidiary structure with broader healthcare portfolio than pure-play pharma.

TypeDirect peer
Description

One of the world's largest pharmaceutical manufacturers with established operations in Egypt spanning vaccines, oncology, and primary care. Co-participant with Sanofi in EDA regulatory discussions, indicating directly comparable market footprint and portfolio breadth.

TypeDirect peer
Description

US multinational pharmaceutical company with presence in Egypt across diabetes, oncology, immunology, and neuroscience. Direct competitor to Sanofi especially in diabetes, an area where Sanofi has a strong therapy-area focus.

TypeDirect peer
Description

British multinational pharmaceutical company with strong presence in Egypt across vaccines, respiratory, and HIV therapy areas. Directly comparable multinational subsidiary model with overlapping therapy-area portfolio.

TypeDirect peer
Description

Multinational pharmaceutical and diagnostics leader with significant presence in Egypt, particularly in oncology and specialty care. Co-participant with Sanofi in EDA regulatory meetings, indicating directly comparable multinational subsidiary structure in Egypt.

TypeDirect peer
Description

US-based multinational pharmaceutical company with established operations in Egypt across oncology, vaccines, and animal health. Comparable multinational subsidiary structure and therapy-area portfolio breadth.

TypeDirect peer
Description

Global Swiss pharmaceutical company operating across innovative medicines and generics (Sandoz), with established Egypt presence. Comparable multinational subsidiary structure with similar branded therapy-area portfolio overlap to Sanofi.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sanofi Egypt

Pharmaceuticalssanofi-aventis.de

Sanofi Egypt is the Cairo-based Egyptian subsidiary of Paris-headquartered pharmaceutical group Sanofi S.A., distributing innovative medicines across multiple therapy areas to Egyptian hospitals, pharmacies, and patients, and engaging with Egypt's Drug Authority on regulatory and investment matters.

What Sanofi Egypt does

Sanofi Egypt is the Cairo-based Egyptian subsidiary of Sanofi S.A., the Paris-headquartered multinational pharmaceutical group publicly listed on Euronext Paris (ticker SAN) with ADRs on NASDAQ. Sanofi Egypt operates within Sanofi's global pharmaceutical manufacturing and commercialization network, distributing innovative medicines across multiple therapy areas — respiratory diseases, diabetes, vaccines, dermatology, cardiovascular, oncology, multiple sclerosis, rheumatology, rare diseases (Gaucher, Pompe), transplant medicine, eosinophilic esophagitis, and thyroid disorders — to Egyptian healthcare providers including hospitals, pharmacies, and patients. The subsidiary is staffed by 10,000+ employees at the global parent level with a local managing director (Adrien Delamare-Deboutteville), and participates actively in regulatory dialogue with Egypt's Drug Authority (EDA) on market access and drug system strengthening.

The company monetizes through pharmaceutical product sales distributed via established healthcare supply chains in Egypt. Pricing models are not publicly disclosed. Distribution reaches Egyptian prescribers and dispensers through standard pharma channels, with parallel support from global Sanofi digital platforms including mein.sanofi.de (patient and healthcare professional portal), the Sanofi Product Database, Medical Information services, and the parent group's Health x Tomorrow digitalization initiative. The Egypt subsidiary is governed by EDA regulatory frameworks and benefits from Sanofi's flexible, internationally-aligned regulatory engagement strategy affirmed in a 2025-11-18 meeting with EDA Chairman Dr. Ali El-Ghamrawy.

Sanofi Egypt sits within a global parent (Sanofi S.A.) that generated approximately €50.3 billion in total FY2023 revenue, with R&D infrastructure spanning biologics, technology platforms, and clinical studies. Sub-brands including Sandoz (generics) and Genzyme (rare disease biotechnology) are part of the parent's portfolio and inform the therapeutic range potentially accessible to the Egyptian market. The Egypt entity itself does not have disclosed standalone revenue, headcount, or Egypt-specific R&D investments in the available data, positioning it as a commercial/regulatory operating subsidiary rather than a standalone R&D hub.

Sanofi Egypt firmographics

Firmographics
Name
Sanofi Egypt
Legal name
Sanofi S.A.
Website
https://sanofi-aventis.de
Company type
Public
Founded year
1973
Operating status
Operating
Headcount range
10,001+ employees
Short description
Sanofi Egypt is the Cairo-based Egyptian subsidiary of Paris-headquartered pharmaceutical group Sanofi S.A., distributing innovative medicines across multiple therapy areas to Egyptian hospitals, pharmacies, and patients, and engaging with Egypt's Drug Authority on regulatory and investment matters.
Ownership category
akta.pro rank

Sanofi Egypt industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAF
Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Pharmaceutical manufacturing
  • Innovative medicines
  • Vaccines production
  • Biopharmaceutical research
  • Therapy area treatments

Where Sanofi Egypt is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Sanofi Egypt business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Sanofi Egypt product offering

Product offering

Core offering

Sanofi Egypt is a pharmaceutical manufacturing subsidiary that develops, manufactures, and distributes innovative medicines across multiple therapy areas including respiratory diseases, diabetes, vaccines, dermatology, cardiovascular diseases, oncology, multiple sclerosis, rheumatology, rare diseases, transplant medicine, eosinophilic esophagitis, and thyroid disorders. The company supports its pharmaceutical portfolio with digital health portals and medical information services for patients and healthcare professionals, and engages with Egypt's Drug Authority to accelerate availability of innovative medicines in the Egyptian market.

Product overview

Sanofi is a research-based biopharma company offering a broad portfolio of innovative therapies across multiple therapy areas including respiratory diseases (asthma, nasal polyps), diabetes, vaccines, dermatology (atopic dermatitis), cardiovascular diseases (cholesterol management), oncology, multiple sclerosis, rheumatology, rare diseases (Gaucher, Pompe), transplant medicine, eosinophilic esophagitis, and thyroid disorders. The company provides patient and healthcare professional-facing digital portals (mein.sanofi.de, product database, medical information services) alongside its therapeutic products. The product portfolio spans both pharmaceutical medications and digital health solutions under the Health x Tomorrow digitalization initiative. Research and development capabilities include biologics and technology platforms supporting drug discovery and manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

  • Sandoz: Generic pharmaceuticals division of Sanofi
  • Genzyme

Products and services

  • Respiratory Disease Treatments (Atemwegserkrankungen) Treatment solutions for respiratory conditions including asthma and nasal polyps, offered as part of Sanofi's pharmaceutical portfolio in Egypt.
  • Diabetes Treatments Diabetes treatment and management pharmaceutical solutions for patients in Egypt.
  • Vaccines (Impfstoffe) Vaccine products and immunization solutions distributed through the Egyptian healthcare supply chain.
  • Dermatology Treatments (Hauterkrankungen) Dermatological pharmaceutical treatments including atopic dermatitis.
  • Cardiovascular Disease Treatments (Herz-Kreislauf-Erkrankungen) Cardiovascular disease pharmaceutical treatments including cholesterol management.
  • Oncology Treatments (Krebserkrankungen) Oncology pharmaceutical treatment solutions for cancer patients.
  • Multiple Sclerosis Treatments (Multiple Sklerose) Neurological disorder pharmaceutical treatments for multiple sclerosis patients.
  • Rheumatology Treatments (Rheumatologie) Rheumatological disease pharmaceutical treatments.
  • Rare Disease Treatments (Seltene Erkrankungen) Orphan disease pharmaceutical treatments including Gaucher disease and Pompe disease.
  • Transplant Medicine Treatments (Transplantationsmedizin) Pharmaceutical treatments for transplant rejection prevention.
  • Eosinophilic Esophagitis Treatments (Eosinophile Ösophagitis) Specialized pharmaceutical treatment for eosinophilic esophagitis.
  • Thyroid Disease Treatments (Schilddrüsenerkrankungen) Thyroid disorder pharmaceutical treatments including thyroid cancer.

Companies that use Sanofi Egypt

Customer profile

Segments1 record

Ideal customer profiles1 record

Sanofi Egypt technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Sanofi Egypt partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Egypt's Drug Authority (EDA)coreStrategic or Co-development Partner · 18 November 2025EDA Chairman Dr. Ali El-Ghamrawy met with Sanofi representatives to discuss mechanisms for strengthening Egypt's drug system and supporting investment. The authority affirmed commitment to flexible regulatory policies aligned with international practices to ensure accelerated availability of innovative medicines and market competitiveness. Sanofi expressed appreciation for EDA's participatory approach, stating cooperation opens prospects for further investment and treatment access in Egypt.
  • AstraZenecaminorOthersPharmaceutical company participating alongside Sanofi in discussions with Egypt's Drug Authority regarding market stability and investment opportunities.
  • SandozminorOthersPharmaceutical company participating alongside Sanofi in discussions with Egypt's Drug Authority regarding market stability and investment opportunities.
  • PfizerminorOthersPharmaceutical company participating alongside Sanofi in discussions with Egypt's Drug Authority regarding market stability and investment opportunities.
  • RocheminorOthersPharmaceutical company participating alongside Sanofi in discussions with Egypt's Drug Authority regarding market stability and investment opportunities.

Recent moves5 records

Expansion highlights5 records

Sanofi Egypt competitors and assessment

Company assessment

Direct peers

  • AstraZeneca: Global multinational pharmaceutical company with a presence in Egypt across oncology, cardiovascular, respiratory, and rare disease therapy areas. Co-participant with Sanofi in EDA regulatory dialogue in 2025, confirming direct market overlap and comparable business model.
  • Pfizer: One of the world's largest pharmaceutical manufacturers with established operations in Egypt spanning vaccines, oncology, and primary care. Co-participant with Sanofi in EDA regulatory discussions, indicating directly comparable market footprint and portfolio breadth.
  • Eli Lilly: US multinational pharmaceutical company with presence in Egypt across diabetes, oncology, immunology, and neuroscience. Direct competitor to Sanofi especially in diabetes, an area where Sanofi has a strong therapy-area focus.
  • GlaxoSmithKline (GSK): British multinational pharmaceutical company with strong presence in Egypt across vaccines, respiratory, and HIV therapy areas. Directly comparable multinational subsidiary model with overlapping therapy-area portfolio.
  • Roche: Multinational pharmaceutical and diagnostics leader with significant presence in Egypt, particularly in oncology and specialty care. Co-participant with Sanofi in EDA regulatory meetings, indicating directly comparable multinational subsidiary structure in Egypt.
  • Merck & Co. (MSD): US-based multinational pharmaceutical company with established operations in Egypt across oncology, vaccines, and animal health. Comparable multinational subsidiary structure and therapy-area portfolio breadth.
  • Novartis: Global Swiss pharmaceutical company operating across innovative medicines and generics (Sandoz), with established Egypt presence. Comparable multinational subsidiary structure with similar branded therapy-area portfolio overlap to Sanofi.

Broad incumbents

  • Johnson & Johnson: Diversified healthcare conglomerate with pharmaceutical operations across immunology, oncology, and neuroscience, with established Egypt presence. Broader portfolio beyond pharma but directly comparable pharmaceutical subsidiary operations.
  • Abbott: Diversified healthcare company with pharmaceutical, diagnostics, nutritionals, and medical devices divisions, with established Egypt presence. Comparable multinational subsidiary structure with broader healthcare portfolio than pure-play pharma.

Regional players

  • Eva Pharma: Leading Egyptian pharmaceutical manufacturer with strong local market presence across branded generics and innovative medicines. Direct competitor to multinational subsidiaries like Sanofi Egypt in the domestic Egyptian pharmaceutical market.

Market position

Strengths4 records

Weaknesses3 records

Competitive moat5 records

Key risks4 records

Key highlights5 records

Customer concentration

Sanofi Egypt social profiles

Digital presence

Sanofi Egypt financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sanofi Egypt leadership team

Management profile

Number of profiles

Profiles1 record

Sanofi Egypt subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Sanofi Egypt funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sanofi Egypt M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanofi Egypt

What does Sanofi Egypt do?

Sanofi Egypt is a pharmaceutical manufacturing subsidiary that develops, manufactures, and distributes innovative medicines across multiple therapy areas including respiratory diseases, diabetes, vaccines, dermatology, cardiovascular diseases, oncology, multiple sclerosis, rheumatology, rare diseases, transplant medicine, eosinophilic esophagitis, and thyroid disorders. The company supports its pharmaceutical portfolio with digital health portals and medical information services for patients and healthcare professionals, and engages with Egypt's Drug Authority to accelerate availability of innovative medicines in the Egyptian market.

Is Sanofi Egypt a public or private company?

Sanofi Egypt is a public company. It is classified as public and is currently operating.

When was Sanofi Egypt founded?

Sanofi Egypt was founded in 1973. It employs 10,001+ people.

Where is Sanofi Egypt based?

Sanofi Egypt is headquartered in Paris, France, in the Europe region.

Who are Sanofi Egypt's main competitors?

Direct peers on record are AstraZeneca, Pfizer, Eli Lilly, GlaxoSmithKline (GSK), Roche, Merck & Co. (MSD) and Novartis. Broad incumbents are Johnson & Johnson and Abbott. Eva Pharma is listed as a regional player.

Does Sanofi Egypt have an API?

No public API is recorded for Sanofi Egypt.

What industry is Sanofi Egypt in?

Sanofi Egypt's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAIAJAF, Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales